Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    E-Cadherin (CDH1) exon deletion in lobular breast carcinoma
    • William G Newman, Senior lecturer
    • Other Contributors:
      • Kristen D Hadfield, Helen J McBurney, Claire Searle, Fiona Lalloo, D Gareth R Evans

    It was with great interest that we read the recent article by Schrader et al. on the low frequency of CDH1 mutations in early-onset and familial lobular breast cancer (1). As detailed by Schrader et al., the cancer syndrome hereditary diffuse gastric cancer (HDGC), in addition to a high risk of diffuse gastric cancer (DGC), is associated with an increased risk of lobular breast carcinoma, a specific histological subtype of...

    Show More
    Conflict of Interest:
    None declared.